Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production.
The new generator technology, developed internally by Telix's IsoTherapeutics team, produces 212Pb via a sealed Thorium-228 (228Th) source, and significantly increases the amount of radioactivity, yield and shelf life compared to currently available 212Pb generators. The fully automated, high-output generators have a small, single hot cell footprint and produce sufficient 212Pb elution for up to 60 clinical doses, with the potential to further scale. The production footprint has been designed to be deployed throughout Telix's (and select partner) manufacturing and distribution networks, including the recently acquired RLS Radiopharmacies network. This development builds on Telix's extensive experience with developing generator-based radiopharmaceutical products.
The novel technology opens new opportunities for the development of alpha-emitting radiopharmaceuticals for use in Telix's next-generation therapeutics pipeline. Lead-212 is a promising isotope for Targeted Alpha Therapy (TAT) but its relatively short half-life (10.6 hours, compared with 9.9 days for actinium-225, 225Ac) and lack of production scale has limited commercial potential. The alpha-emitting profile of 212Pb also has practical synergies with engineered antibodies being developed using Telix's newly acquired discovery platform[1], with pharmacology and clearance organ characteristics that are well suited to its short half-life.
Chad Watkins, General Manager, Isotope Strategy, Telix, said, "A lead-212 generator that produces minimal waste and fits within the current radiopharmacy footprint is a step change in the production of this alpha emitting therapeutic radioisotope. It creates the potential for commercial scale lead-212 isotope production that wasn't possible before and opens up new pathways for matching this promising alpha isotope with a range of targeting agents."
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations
Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com
Legal Notices
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.
[1] Telix ASX disclosure 31 January 2025.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/telix-adds-lead-212-isotope-production-capability-302400465.html
SOURCE Telix Pharmaceuticals Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
11 minutes ago
- Business Upturn
Ericsson bags multi-year NOC Managed Services contract with Bharti Airtel
Ericsson (NASDAQ: ERIC) has been awarded a significant multi-year Network Operations Center (NOC) Managed Services contract by Bharti Airtel, reinforcing the strong and enduring partnership between the two telecom giants. This strategic collaboration highlights Ericsson's leadership in managed services and its commitment to delivering superior network performance and value to Airtel's customers. Under this new agreement, Ericsson will deploy its advanced intent-based operations through a centralized NOC to efficiently manage Bharti Airtel's diverse network services. These include 4G, 5G Non-Standalone (NSA), 5G Standalone (SA), Fixed Wireless Access (FWA), Private Networks, and Network Slicing. The move aims to enhance network reliability, scalability, and innovation across Airtel's pan-India footprint. Ericsson's state-of-the-art NOC will play a crucial role in managing and scaling Airtel's expansive network infrastructure, especially focusing on expanding Fixed Wireless Access and Network Slicing capabilities throughout the country. This will empower Airtel to offer improved connectivity solutions and cater to evolving customer demands in the 5G era. Randeep Sekhon, CTO of Bharti Airtel, stated, 'We are excited to enhance our strong collaboration with Ericsson as we pursue our goal of creating a future-ready network that delivers an exceptional experience for our customers. We believe that these innovative technologies will empower us to meet the growing data demands of consumers in a digitally connected India.' With a partnership spanning over 25 years, Ericsson and Bharti Airtel have collaborated across multiple generations of mobile communication technologies. This latest contract follows Airtel's recent collaboration with Ericsson on 5G Core technology, further driving the evolution of India's 5G ecosystem. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
29 minutes ago
- Yahoo
GitLab (GTLB) Reports Q1: Everything You Need To Know Ahead Of Earnings
Software development tools maker GitLab (NASDAQ:GTLB) will be reporting earnings tomorrow after the bell. Here's what you need to know. GitLab beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $211.4 million, up 29.1% year on year. It was a slower quarter for the company, with full-year EPS guidance missing analysts' expectations significantly and EPS guidance for next quarter missing analysts' expectations significantly. Is GitLab a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting GitLab's revenue to grow 25.9% year on year to $213 million, slowing from the 33.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.15 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. GitLab has missed Wall Street's revenue estimates twice over the last two years. Looking at GitLab's peers in the software development segment, some have already reported their Q1 results, giving us a hint as to what we can expect. JFrog delivered year-on-year revenue growth of 22%, beating analysts' expectations by 4.4%, and Fastly reported revenues up 8.2%, topping estimates by 4.8%. JFrog traded up 10.9% following the results while Fastly was also up 26.8%. Read our full analysis of JFrog's results here and Fastly's results here. There has been positive sentiment among investors in the software development segment, with share prices up 2.6% on average over the last month. GitLab is down 5.4% during the same time and is heading into earnings with an average analyst price target of $70.36 (compared to the current share price of $49.27). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Business Insider
an hour ago
- Business Insider
Nvidia or Palantir: Morgan Stanley Selects the Superior AI Stock to Buy
A smart investor is always on the lookout for growth sectors, places where the economy is primed to boom and where consequent opportunities are riding high. Right now, few sectors are offering the strong growth potential of artificial intelligence (AI). Confident Investing Starts Here: In just a few short years, AI – and particularly generative and agentic AI – has become the 'shiny new thing' on the cutting edge of high-tech. The entry of AI is rapidly transforming the tech industry, and it is making inroads into numerous other areas. Data management, content creation, publishing – we've only begun to find out what AI can do, and we can only imagine what it will do. A report from UN Trade & Development points out that the world's AI market, which was estimated at $189 billion in 2023, will expand 25x by 2033 to reach $4.8 trillion. AI's growth will bring with it gains for companies across a wide spectrum of fields, including development, applications, hardware, infrastructure, and power generation. Such rapid growth is creating new opportunities for investors. The challenge won't be finding one – it'll be choosing the right one. That's where Morgan Stanley's analysts come in. They've zeroed in on two tech titans that have become synonymous with AI innovation: Nvidia (NASDAQ:NVDA) and Palantir (NASDAQ:PLTR). Both are riding the AI wave, but Morgan Stanley is making a clear call on which one stands out as the better buy right now. Let's take a closer look. Nvidi a Nvidia stands at the forefront of Wall Street's tech revolution. As a dominant force among the 'Magnificent 7' and boasting a $3.45 trillion market cap, it's not only the largest of the tech mega-cap – it's the biggest publicly traded company in the U.S. The AI boom, which took off in late 2022 with the debut of ChatGPT, put Nvidia in the spotlight. As the top supplier of high-performance GPUs, the company was well-positioned to meet the explosive demand for AI-capable chips – and that sent NVDA shares soaring 660% over the past three years. However, even a juggernaut like Nvidia isn't immune to shifting market dynamics. After an extraordinary run, the company's stock momentum has started to cool amid rising volatility this year. One key challenge stems from the lingering effects of President Trump's tariff policies. The chip industry is deeply intertwined with global supply chains, and Nvidia's exposure to East Asia has made it vulnerable to tariff risks. That may be easing now, as both China and the EU have entered into trade talks with the White House. Yet, Nvidia isn't standing still. The company continues to push the boundaries of innovation, doubling down on emerging technologies to maintain its leadership in the AI race. This past May, Nvidia unveiled the world's largest dedicated quantum computing research supercomputer, the ABCI-Q, hosted at the Global Research and Development Center for Business by Quantum-AI Technology (G-QuAT). The new system is already integrated with Nvidia's open-source hybrid computing platform CUDA-Q. A second new development was made public last week. Nvidia announced that its Blackwell architecture, designed to power the latest AI platforms, showed superior performance on the latest rounds of the MLPerf Training, a key benchmark used to rate the capabilities of new AI systems. In Nvidia's last earnings report, covering fiscal 1Q26, company CEO Jensen Huang noted that the company's breakthrough Blackwell products are in full production and went on to outline the potential for AI to continue supporting strong results: 'Global demand for NVIDIA's AI infrastructure is incredibly strong. AI inference token generation has surged tenfold in just one year, and as AI agents become mainstream, the demand for AI computing will accelerate.' Turning to the company's financial results for the quarter, we find that Nvidia's revenue came in at $44.1 billion, up 69% year-over-year and $810 million better than had been expected. The company's non-GAAP EPS figure, at 81 cents, was 6 cents per share above the forecasts. Data center revenue, at $39.1 billion, was the main revenue driver and was up 73% year-over-year. Nvidia's gross margin for the quarter was reported at approximately 61%. For 5-star analyst Joseph Moore, the key point for investors to remember about Nvidia is that the future looks good. The Morgan Stanley analyst writes in his note on this chip maker: 'Racks get better from here. China is entirely derisked, at least for direct shipments, and we are optimistic that there will be some path to monetize at least a portion of that demand. Gross margins have bottomed and are improving to the mid 70s, sustainably. And every customer commentary confirms that customers waiting for these new technologies have left demand on the table. So our confidence in durable demand drives is quite high. We think that our numbers are conservative given the variables at play, and we see a high probability of continued upward revisions.' Moore's comments support his Overweight (i.e., Buy) rating on NVDA stock, while his $170 price target points toward a one-year upside potential of 20%. (To watch Moore's track record, click here) Overall, Nvidia has earned a Strong Buy consensus rating from the Street's analysts, based on 40 reviews that include 35 Buys, 4 Holds, and 1Sell. The stock is priced at $141.72 and its $172.36 average price target implies a ~22% upside in the next 12 months. (See NVDA stock forecast) Palantir Technologies Palantir is another standout in the AI space. Founded in 2003 by venture capitalist Peter Thiel, the company has built a strong reputation as a leader in data analytics and software solutions. Like Nvidia, Palantir has leveraged its unique capabilities to ride the wave of the AI boom, and the results have been striking. Over the past three years, its stock has skyrocketed 1,291%, including a 69% gain year-to-date. These gains haven't come by chance. Palantir stock's growth is rooted in the strength of its data management and analysis tools, which are used by businesses, non-profits, and government agencies alike. At the center of its offerings is the AI Platform (AIP), a solution that blends advanced AI capabilities with human-driven decision-making. One of its key strengths lies in its accessibility – users can interact with the platform using natural language, without needing coding expertise. AIP also supports multilingual inputs and translation frameworks, making it easier for users around the world to engage with its tools. Palantir can currently boast more than 760 customers, from both the public and private sectors. The company's AI-powered data platforms are popular with big businesses, and Palantir can count such names as Stellantis and BP among its users, as well as the US Department of Defense. In May, Palantir received a $795 million contract modification to its Maven Smart System agreement with the Army, extending support through 2029. The company is also among the short‑listed firms – alongside SpaceX, Lockheed Martin – and others, being considered for President Trump's $175 billion Golden Dome missile defense program. On the financial side, Palantir has been singularly successful at generating strong revenues and earnings. In 1Q25, the last period reported, the company had a top line of $883.9 million, representing 39% year-over-year growth and beating the forecast by $21.72 million. At the bottom line, Palantir's EPS came to 13 cents in non-GAAP terms, matching analyst expectations. The company proved successful at closing large deals during the quarter, including 31 deals worth at least $10 million. Despite this strength, some caution is warranted. Morgan Stanley's Sanjit Singh remains confident in Palantir's fundamentals but cautions that the valuation may be stretched after such a strong run. 'Palantir continues to prove out that it is one of the clear AI winners in software which has translated to accelerating top-line growth of 30%+ and a rule of 40 score (revenue growth + operating margin) of 83%. While this represents elite level performance in software, the current valuation of ~95x CY27 FCF makes underwriting a return on Palantir shares extremely challenging. As a result, we remain EW and await a better entry point before getting more bullish,' Singh noted. Singh's Equal Weight (i.e., Hold) rating comes with a $98 price target, implying a potential 25% drop from current levels. It's safe to say that his ideal entry point lies somewhere south of that. (To view Singh's track record, click here) Morgan Stanley's view aligns with the broader Street consensus. Palantir holds a Hold rating overall, based on 18 recent analyst recommendations: 3 Buys, 11 Holds, and 4 Sells. The stock is currently trading at $127.72, while the average price target stands at $100.13, implying a potential ~22% downside over the coming year. (See PLTR stock forecast) With the facts laid out, the Morgan Stanley analysts come to a clear conclusion: Both of these AI stocks are solid performers, but Nvidia is the superior choice to buy right now. To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
